



Managing Bipolar Disorder From Urgent Situations to Maintenance Therapy, Part 1: Urgent Situations

This ACADEMIC HIGHLIGHTS section of The Journal of Clinical Psychiatry presents the highlights of the planning teleconference series "Managing Bipolar Disorder From Urgent Situations to Maintenance Therapy, Part 1: Urgent Situations," which was held in March and April 2007. This report was prepared by the CME Institute of Physicians Postgraduate Press, Inc., and was supported by an educational grant from Eli Lilly and Company.

The planning teleconference series was chaired by **Rakesh Jain, M.D., M.P.H.**, from R/D Clinical Research, Inc., Lake Jackson, Tex. The faculty were **J. Sloan Manning, M.D.**, from the Mood Disorders Clinic, Moses Cone Family Practice Residency, and private practice, Greensboro, N.C.; **Steven Garlow, M.D., Ph.D.**, from the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga.; and **Tracey G. Skale, M.D.**, from the Greater Cincinnati Behavioral Health Services, Cincinnati, Ohio.

In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME article were asked to complete a statement regarding all relevant financial relationships between themselves or their spouse/partner and any commercial interest (i.e., a proprietary entity producing health care goods or services consumed by, or used on, patients) occurring within the 12 months prior to joining this activity. The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows: **Dr. Jain** is a consultant for Cyberonics, Addrenex, Eli Lilly, Impax, and Takeda; has received grant/research support from Abbott, GlaxoSmithKline, Eli Lilly, and Merck; and is on the speakers or advisory boards for Cyberonics, GlaxoSmithKline, Eli Lilly, and Roche. **Dr. Manning** is a consultant for and is on the speakers or advisory boards for Eli Lilly and AstraZeneca. **Dr. Garlow** is a consultant for Eli Lilly and Solvay, has received grant/research support from Janssen, has received honoraria from the Postgraduate Institute of Medicine, and is on the speakers or advisory boards for Eli Lilly and Pfizer. **Dr. Skale** is a consultant for, has received honoraria from, and is on the speakers or advisory boards for Eli Lilly.

The opinions expressed herein are those of the faculty and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter.

Introduction: Taking Control of Urgent Situations in Bipolar Disorder

Urgent is defined as "calling for immediate attention."¹ Rakesh Jain, M.D., M.P.H., emphasized that patients with bipolar disorder often demand immediate attention from clinicians because these patients are at a high risk for situations that are urgent or that may trigger urgency, such as suicidality, aggression, legal difficulties, functional disability, occupational disruption, and marital disharmony.

Patients with bipolar disorder have a significant risk for suicide. A longitudinal study² of patients with bipolar disorder reported a standardized mortality ratio of 9.77 (95% CI = 4.22 to 19.24) when compared with the general population. Further, clinicians have long been aware of the common occurrence of aggression or agitation in uncontrolled bipolar disorder.³ The National Comorbidity Survey (NCS)⁴ and the Epidemiologic Catchment Area Survey⁵ found high rates of violence among patients with bipolar disorder (16% and 11%, respectively). Uncontrolled bipolar disorder also increases individuals' risk for criminal arrest, sending many patients with this condition on a collision course with the judicial system and creating clinical urgency for rapid intervention to avoid incarceration.⁶

Bipolar disorder is also associated with severe impairment of functioning in social, vocational, and cognitive domains.⁷ Thus, Dr. Jain noted that functional disability appears to be the rule and not the exception. Relationships and marriages are adversely affected when a partner suffers from bipolar disorder. For example, evidence⁸ has

shown higher rates of sexual dissatisfaction and lower rates of affection, support, and consideration for spouses of patients with bipolar disorder, resulting in high rates of marital discord in this population. In terms of vocation, according to the NCS Replication,⁹ patients with bipolar disorder lost 65.5 workdays per year. When compared with patients with major depressive disorder who lost 27.2 workdays per year, bipolar disorder emerges as one of the most disabling psychiatric conditions.

Clinicians have an important role in the quick and efficient identification and resolution of urgent situations for patients with bipolar disorder. Dr. Jain stated that although clinicians are moved by the plight of urgently ill patients afflicted by bipolar disorder, many do not feel confident on how to best diffuse urgent situations and move patients to stability. This Academic Highlights, featuring 3 experienced experts from multiple settings, provides evidence-based recommendations and clinical advice on helping urgently ill patients with bipolar disorder.

First, J. Sloan Manning, M.D., emphasizes that patients who present in an urgent situation may be in a mixed phase of bipolar disorder, and correct diagnosis is critical for stabilization.^{10,11} Then, Steven J. Garlow, M.D., Ph.D., summarizes the pharmacologic management of urgently ill patients, whether in new-onset or breakthrough episodes. Oral, orally disintegrating, and intramuscular medication formulations are all effective treatment options available to clinicians. Additionally, the American Psychiatric Association

(APA) guidelines support the use of rational polypharmacy in treating severely ill patients who need urgent and rapid control of symptoms. Finally, Tracey G. Skale, M.D., recommends the practical application of the biopsychosocial approach in treating urgently ill patients with bipolar disorder,

which can help clinicians comprehensively employ all treatment modalities. All the experts advocate implementing psychoeducation and psychotherapy, which have demonstrated effectiveness in helping optimize outcomes for patients with bipolar disorder.¹²

trait mixing,¹⁷ was described in which patients with predominantly depressive temperaments (early-onset habitual personality traits) carried those depressive temperaments into a manic episode. Conversely, people who had early-onset habitual manic temperaments carried that mania into a major depressive episode, thus producing a mixing of symptoms that was clinically evident.

Akiskal and Mallya¹⁸ created a clinically useful list (Table 1) of features of mixed states. One feature is the presence of unrelenting dysphoria. These bipolar patients get very little rest from their psychic pain. They are generally severely agitated, have refractory anxiety, often present with unendurable sexual excitement, and have difficult-to-treat insomnias. These patients also suffer from suicidal obsessions and impulses. Patients can present with histrionic demeanors, appearing to seek attention for attention's sake, and yet it is obvious during examination that their suffering is genuine and intense.

Epidemiology of Bipolar Mixed States

Dr. Manning reported that epidemiology studies of mixed states suggest a lifetime prevalence of approximately 40% in hospitalized patients with bipolar I disorder.^{19,20} Mixed states seem to be more common in women than in men. This point was illustrated by Suppes et al.,²¹ from the Stanley Foundation Bipolar Treatment Outcome Studies, in which depression was found in those who met the criteria for hypomania significantly more often in women than in men (72% vs. 42%, respectively; $p < .001$). High levels of anxious symptomatology are also present in mixed states and seem to correlate with the presence and severity of depressive symptomatology.^{22,23} Anger, irritability, and impulsive irritability are also increased during mixed states,²⁰ perhaps leading to the observed elevated suicide risk in mixed states.^{13,23-27}

Bipolar Mixed States: The Importance of a Correct Initial Diagnosis

Bipolar illness is pleomorphic, according to Dr. Manning. Because manic and depressive symptoms often appear concurrently and are often comorbid with other features of psychopathology, these symptoms can be easily confused with those of other psychiatric illnesses or missed altogether in the clinical process. An assessment for mixed episodes and/or mixed states is an important part of the clinical evaluation of any depressed and anxious patient, because morbidity and comorbidity among bipolar mixed presentations are greater than among pure manic or pure depressive states, particularly in the realm of suicidality. Without an early and correct diagnosis, the patient may receive medications that could exacerbate the mixed state.

Concepts of Mixed States

The key concept in understanding the bipolar mixed state, according to Dr. Manning, is that mood, cognition, and psychomotor energy can move independently of each other in bipolar disorder. This independence gives rise to superimpositions of the extremes of a pure mood state with cognitive or psychomotor features of the opposite mood. Thus, bipolar disorder can present in these mixed states with a perplexity of symptomatology that can be clinically confusing.¹³

DSM-IV-TR concept of mixed states. Dr. Manning stated that the concept of mixed episodes from the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition,

Text Revision (DSM-IV-TR)¹⁴ is categorical and limited. The DSM-IV-TR concept requires at least 1 week when the criteria for both a manic episode and a major depressive episode are met nearly every day. The characteristics discussed in the DSM-IV-TR include rapidly fluctuating mood, agitated states, severe insomnia, psychotic features, and an increase in suicidal thinking. The DSM-IV-TR excludes mixed features that would be direct physiologic effects of general medical conditions. For example, the omission of neurologic disorders, such as multiple sclerosis or stroke, and hypermetabolic states, such as adrenal dysfunctions or thyrotoxicosis, may complicate the recognition and diagnosis of mixed states. The DSM-IV-TR also excludes the effects of substances and treatments such as amphetamines, neurotoxins, antidepressants, and electroconvulsive therapy. The issue of whether antidepressant-induced manic switches or mixed states are specific to bipolar I disorder remains a matter of controversy.

Other concepts of mixed states. Non-DSM-IV-TR concepts for mixed mood states include dimensional mixing and trait mixing. Dimensional mixing includes dysphoric mania¹⁵ and depressive mixed states.¹⁶ Dysphoric mania is a manic state combined with either 2 or 3 depressive symptoms, depending on which definition of dimensional mixing is observed.¹⁵ Depressive mixed states are defined as major depression with 3 or more hypomanic symptoms.¹⁶ An even newer concept,

Table 1. Features of Mixed States^a

Unrelenting dysphoria Severe agitation Refractory anxiety Unendurable sexual excitement Intractable insomnia Suicidal obsession and impulses Histrionic demeanor Genuine, intense suffering
^a Data from Akiskal and Mallya. ¹⁸

Mortality Associated With Bipolar Mixed States

Suicidal behavior, both nonfatal and fatal, is increased during mixed episodes.²³ Risk factors for suicide include a family history of suicide, a history of physical or sexual abuse, an early age at onset of bipolar disorder, severe depressive symptoms (especially when presenting with hopelessness), and any comorbid Axis I disorder, particularly anxiety disorders or substance use disorders.²⁴ The presence of a mixed state or extreme rapid cycling also increases patients' suicide risk.²³

Several studies have documented higher levels of suicidality in patients with mixed states versus patients with pure mania: Dilsaver and colleagues²⁵ showed a 55% suicidality rate in mixed states versus 2% in pure mania, Strakowski et al.²⁶ found a 26% suicidality rate in mixed states versus 7% in pure mania, and Marneros et al.²⁷ found a 14% rate of suicidality in mixed states versus 0% in pure mania. Dr. Manning emphasized that patients' potential mortality should always be in the clinician's mind during evaluations for mixed states. This mindfulness will lead to both an accurate diagnosis of the bipolar diathesis and an accurate gauge of the extent of clinical severity of the disorder.

Opportunities for and Consequences of Misdiagnosis

Bipolar disorders are prevalent in primary care settings, yet misdiagnosis and diagnostic delays are common. In 2 studies, 27.9%²⁸ and 25.9%²⁹ of patients presenting with depression or anxiety in primary care settings had some form of bipolar disorder. Dr. Manning stated that, over the last

Table 2. Social and Economic Consequences of Mixed States

Marital disruption(s) ³¹ Work disruption(s) ³² Job loss(es) ³¹ Arrests ³² High use of medical resources ³¹

decade, there has been a broad focus on unipolar depression and a variety of anxiety disorders, which may have distracted some clinicians from bipolar disorder as an important clinical entity. The manifestations of mania are much less familiar to clinicians in nonpsychiatric settings where the majority of mood disorder treatment is administered.^{28,30}

Because the concept of mixed states is unfamiliar to many clinicians, there is a tendency for physicians to focus on a comorbidity or state descriptors in these patients and miss the larger picture of the underlying bipolar diathesis. Physicians may also attribute social or economic consequences of mixed states to issues that are unrelated to the mood disorder (Table 2).^{31,32} Misdiagnosis can cause patients to remain in mood states with high levels of suicidal thinking, impulsivity, anger, and/or aggressive tendencies, which may cause further difficulties at home, at work, in community activities, and other areas of life.

Anxiety disorders and suicidal-like behaviors—including self-mutilation—occur often in patients with bipolar disorder, with many patients experiencing panic attacks or prolonged panic states, symptoms of obsessive-compulsive disorder, generalized anxiety disorder or social phobia, and substance use disorders.^{23,33,34} These symptoms can distract physicians from the presence of a bipolar mixed state. Additionally, clinicians may focus on agitation and make a diagnosis of agitated depression.¹³ Not all agitated depressions are signs of bipolar disorder; however, agitation in a patient who presents with depression is an indication to look carefully for other elements of the bipolar diathesis. Dr. Manning noted that another potential

misdiagnosis is borderline personality disorder.

Patients may receive inappropriate treatment if physicians fail to diagnose a bipolar diathesis.^{29,30} For example, patients with refractory insomnia may get overmedicated with sedative-hypnotics.¹⁸ Clinicians may also focus on depression or anxiety and treat patients with an antidepressant, as opposed to using treatments more specific for a bipolar mixed state. Treatment with antidepressant monotherapy tends to increase the potential for suicidality, impulsivity, and aggressive tendencies.^{35,36} Dr. Manning stressed that it is possible to exacerbate the condition of already ill individuals if they are not accurately diagnosed and treated.

Conclusion

Symptoms of mania and major depression may be mixed in patients with bipolar disorder, and increased morbidity and mortality are associated with mixed states. Dr. Manning stated that early recognition of the bipolar diathesis and mixed states permits appropriate interventions that may reduce morbidity and mortality, and thus, improve patient outcome.

Interventions for Acute Mood Episodes in Patients With Bipolar Disorder

Types of Acute Mood Episodes

Dr. Garlow discussed pharmacotherapy for 3 types of acute, rapid-onset mood episodes in bipolar disorder—manic, depressive, and mixed. These mood episodes are defined by DSM-IV criteria¹⁴; however, Dr. Garlow added that, in manic episodes, patients can have severe behavioral disturbances, activation, psychosis, and severe agitation; in depressive episodes, patients can have significant neurovegetative symptoms and psychosis; and in mixed bipolar episodes, which are a mixture of manic and depressive symptoms, patients can have significant agitation and distress, as well as psychosis.

Treatment Goals

The first treatment goal for an acute mood episode is rapid and robust relief of symptoms. For manic episodes, initial interventions should calm patients to de-escalate their mania, relieve psychotic symptoms, and alleviate behavioral disturbances not only for patients' well-being, but for those around them as well. For depressive episodes, the goal is rapid relief from the negative symptoms, cognitive disturbances, and impairments resulting from depression. When treating an acute episode, Dr. Garlow recommended that clinicians select a treatment that facilitates the transition into maintenance therapy and prevents cycling and further decompensation.

Urgent treatment is critical for patients experiencing acute mood episodes for 3 reasons: (1) To prevent hospitalization or to shorten the hospital stay. Often, patients will feel demoralized and discouraged as a result of hospitalization.³⁷ Further, this treatment modality is costly, not only for the patient, but for society as a whole.³⁷ (2) To reduce the risk for suicide, which is high among patients with bipolar disorder.³⁸ Dr. Garlow commented that mixed episodes may combine the energy and activation of mania with the negative mood of depression, which has the potential to result in fatal outcomes for patients. (3) To reduce the psychosocial consequences that adversely affect patients' familial relationships, employment, and status with the law.³²

According to Dr. Garlow, mental health practitioners typically encounter 2 treatment scenarios: new-onset mood episodes or breakthrough episodes. Patients with new-onset mood episodes are either at the beginning of the disease and not yet in treatment or were on maintenance therapy but have stopped taking medication for a variety of reasons. Patients with a breakthrough episode are on active maintenance therapy but nevertheless experience an acute mood episode. Dr. Garlow described each treatment scenario and discussed available treatment options, including those with U.S. Food and Drug Admin-

Table 3. FDA-Approved Agents for the Treatment of Various Bipolar Disorder States

Agent	Agitation	Type of Mood Episode			Maintenance Therapy
		Manic	Mixed	Depressed	
Aripiprazole ⁴⁰	✓ ^a	✓	✓		✓
Carbamazepine ⁴⁵		✓ ^a	✓ ^a		
Chlorpromazine ⁴⁷		✓			
Divalproex ⁴⁴		✓ ^a	✓ ^a		
Lamotrigine ⁵⁹					✓
Lithium ⁴³		✓			✓
Olanzapine ³⁹	✓ ^a	✓	✓		✓
Olanzapine-fluoxetine ⁵⁰				✓	
Quetiapine ⁴⁹		✓	✓	✓	
Risperidone ⁴⁸		✓	✓		
Ziprasidone ⁴¹		✓	✓		

^aExtended-release or intramuscular injectable formulations indicated.
Symbol: ✓ = approved by the U.S. Food and Drug Administration (FDA).

istration (FDA) indications, to promote optimal patient outcomes.

Acute Manic and Acute Mixed Episodes

Agitation. An emergent symptom of acute mania (either new-onset or breakthrough) is psychomotor agitation, which is generally defined as excessive motor activity associated with a feeling of inner tension and requires definitive and immediate intervention. Patients can manifest high levels of motor agitation, impulsivity, and lability, which may lead to exhaustion. The experience has a large component of fear and uncertainty and can be highly distressing and uncomfortable for patients, who can be threatening because they themselves feel threatened. Agitation can interfere with care via threatening and escalating behaviors that lead to high-risk situations with untoward consequences. When agitation is combined with psychosis, misperceptions of the world are added to patients' already negative and fearful experiences and may result in self-injury or dangerous situations for family members and staff.

Rapid physical intervention may be necessary, such as putting the patient into seclusion or restraints. However, Dr. Garlow strongly recommended using oral agents to treat acute agitation if possible, because convincing patients to take medication allows for the development of a therapeutic alliance with the treatment provider, whereas restraining patients and forcing medication through injection creates a con-

flictual relationship. Dr. Garlow acknowledged that, in extreme cases, an intramuscular medication may be necessary, with the treatment goal of helping patients remain calm, awake, and able to participate in their evaluation and treatment.

Although 2 second-generation antipsychotics, intramuscular olanzapine³⁹ and intramuscular aripiprazole,⁴⁰ have been approved by the FDA to treat psychomotor agitation in bipolar I mania, Dr. Garlow stated that intramuscular ziprasidone⁴¹ (a second-generation antipsychotic) and lorazepam⁴² (a benzodiazepine with anxiolytic properties that is often used alone or in combination with an antipsychotic medication) are other agents typically used in acute interventions for agitation (Table 3). At one time, haloperidol was the standard treatment for agitation and is still currently used; however, Dr. Garlow recommended using second-generation antipsychotics instead.

New-onset manic or mixed episodes. For patients without agitation, treatment options are greater for acute manic and acute mixed episodes. Dr. Garlow advised that, when making a pharmacotherapeutic decision, clinicians should consider patients' past experiences with particular agents, such as response, allergic reactions, contraindications, route of administration, and onset of action, including the introduction of an agent at a full therapeutic dose or an extended period of dose titration and the ease of transition of an agent into maintenance therapy.

Lithium⁴³ is the standard treatment for acute manic episodes; however, extended-release divalproex sodium⁴⁴ and carbamazepine⁴⁵ also are indicated for treating acute manic episodes (see Table 3). Dr. Garlow described treatment strategies to gain rapid control for an acute manic episode: with divalproex, aim for a blood level above 100 µg/mL; with carbamazepine, aim for a blood level about 12 µg/mL; and with lithium, the blood level should be raised to between 1.0 and 1.2 mEq/L. Dr. Garlow advised that all 3 agents may present issues when titrating dosages.

Several antipsychotic agents are indicated for treating acute manic episodes,⁴⁶ including the oral and injectable formulations of chlorpromazine.⁴⁷ The second-generation oral antipsychotics risperidone,⁴⁸ olanzapine,³⁹ quetiapine,⁴⁹ ziprasidone,⁴¹ and aripiprazole⁴⁰ are also approved for the treatment of acute mania as well as for the treatment of acute mixed episodes. Other agents approved for the treatment of mixed episodes are the extended-release formulations of carbamazepine⁴⁵ and divalproex⁴⁴ (see Table 3).

Breakthrough mania. Dr. Garlow stated that maximizing the dose of the current agent should be the first intervention for patients on maintenance therapy who have persistent symptoms or who have an emergent manic episode. Dr. Garlow suggested that, for patients treated with lithium, the blood level should be raised to between 1.0 and 1.2 mEq/L, and for patients treated with valproic acid, the blood level should be brought up above 100 µg/mL, in the 100 to 120 µg/mL range. If symptoms persist after optimizing the maintenance agent, Dr. Garlow recommended adding a second-generation antipsychotic, several of which have shown benefit in an adjunctive capacity.⁴⁶ For example, for patients taking lithium or valproic acid, risperidone⁴⁸ and olanzapine³⁹ are indicated for emergent mania or mixed episodes and quetiapine⁴⁹ is indicated for emergent mania. Consideration should be given to the agent's rapid onset of action and symptom relief, as well as

the potential of the medication to transition into maintenance therapy.

Acute Depressive Episodes

New-onset bipolar depression. Treatment decisions for people who have been diagnosed with bipolar disorder but are not currently on maintenance therapy depend on individual patient's past experiences, the clinician's understanding of the patient's preferences, and the patient's course of illness. The olanzapine-fluoxetine combination⁵⁰ is indicated by the FDA for treatment of bipolar depression, as is quetiapine⁴⁹ (see Table 3). Other pharmacologic interventions supported by evidence⁵¹ include lithium alone or in combination with an antidepressant, valproic acid alone or in combination with an antidepressant, and lamotrigine.

Treating bipolar disorder with antidepressants is a controversial issue because these agents may lead patients to switch rapidly from depression into mania and thus begin a rapid-cycling phase.^{52,53} Dr. Garlow stressed that, if antidepressants are used in patients with bipolar disorder, a mood-stabilizing medication, such as lithium, valproic acid, or olanzapine, should be co-administered to prevent rapid-cycling. Meta-analyses^{54,55} have shown that antidepressants relieve acute depressive symptoms in bipolar disorder; however, the long-term value is yet to be established. In terms of treatment for patients who switch into a manic episode, selective serotonin reuptake inhibitors (SSRIs) may be less problematic than tricyclic antidepressants (TCAs).⁵⁵

Breakthrough depression. For a patient currently receiving maintenance therapy, the first intervention for breakthrough depression should be to check the patient's blood drug level and titrate the maintenance agent up to a full therapeutic dose. Dr. Garlow reminded clinicians that when a patient who has previously been stable on maintenance therapy begins to present with some mood symptoms, previous mood cycles predict the next one.⁵⁶ For example, someone who has had several depres-

sive episodes is more likely to have another depressive episode rather than a manic episode. An antecedent of breakthrough mania is sleep disturbance, whereas the antecedents of a depressive episode are anxiety, poor concentration, and indecisiveness, as well as depressive symptoms.

If the patient is still depressed after optimizing the current mood stabilizer, the next step should be to consider additional medications, such as a second-generation antipsychotic, lamotrigine, or an antidepressant.^{57,58} Scant definitive evidence is available to aid in decision-making, but clinicians should take into account previous beneficial treatments for the patient, contraindicated medications, and the patient's opinions, expectations, and concerns regarding particular treatments.

Two second-generation antipsychotics are approved for treating breakthrough bipolar depression—the olanzapine-fluoxetine combination⁵⁰ and quetiapine⁴⁹ (see Table 3). Olanzapine monotherapy is FDA-indicated for maintenance therapy in bipolar disorder,³⁹ which may facilitate patients' transition into maintenance therapy when treated with the olanzapine-fluoxetine combination for acute depression. Other agents with indications for maintenance treatment are lamotrigine⁵⁹ and lithium,⁴³ and the efficacy of aripiprazole has also been demonstrated for maintenance treatment in patients stabilized after recent manic or mixed episodes⁴⁰ (see Table 3).

Conclusion

Dr. Garlow emphasized that when making treatment decisions for patients with acute mood episodes, clinicians should consider patients' cycling history, course of illness, past and current treatment history, and the urgency of the clinical situation. If catastrophic events are likely, agents with rapid onset of action should be chosen to avoid adverse social consequences and hospitalization. Additionally, clinicians should opt for pharmacotherapeutic options that will ease patients' transition into maintenance therapy.

Practical Strategies for Assessing and Stabilizing Patients With Bipolar Disorder in Urgent Situations

Dr. Skale recommended that, when faced with a patient in an urgent bipolar situation, clinicians ask specific questions on a routine basis (Table 4). If clinicians do not inquire about important issues, patients could face negative consequences. In urgent situations, the clinician has a responsibility to act as quickly as possible to rapidly reduce acute symptoms and help the patient avoid hospitalization and the loss of relationships, independence, and employment, as well as the resulting demoralization from these events. Fortunately, multiple treatment modalities and management strategies are available for clinicians to stabilize the patient in acute distress.

Biopsychosocial Model

Effective management of bipolar disorder involves all aspects of patients' lives—biological, psychological, and social—that can trigger acute manic, depressive, or mixed episodes. Therefore, Dr. Skale described the biopsychosocial model of bipolar disorder and stated that this model helps physicians, patients, and patients' families to understand what may have caused the development of an urgent situation and how to best resolve it (Figure 1).

Biological Management of Urgent Situations

Biological factors may complicate the pharmacologic management of patients with bipolar disorder and may also induce urgent situations. These factors include nonadherence to treatment regimens, comorbid medical conditions, hormonal changes due to pregnancy or childbirth, substance use, sleep disturbance, and overall worsening of bipolar illness. For example, comorbid medical illnesses and hormonal changes may affect the successful management and stabilization of patients' moods. If comorbid medical

conditions are present, the acute psychiatric condition should be controlled as soon as possible so that the nonpsychiatric condition may be addressed. For pregnant patients with bipolar disorder, clinicians' threshold for hospitalization in a high-risk situation may be lower than for patients who are not pregnant. However, when treating patients who are pregnant and in urgent situations, Dr. Skale recommended that lithium, valproate, and other anticonvulsants be avoided during the first trimester.⁶⁰⁻⁶² In addition, women with bipolar disorder are at a high risk for relapse (approximately 50%) into mania, depression, or psychosis immediately postpartum, which also increases their risk for developing an urgent situation.⁶³

Patients with bipolar disorder have higher rates of substance use than the general population (41% vs. 6%, respectively),⁶⁴ and those with comorbid substance use disorders are more likely to harm themselves than those without substance use disorders.⁶⁵ Additionally, alcohol-related dehydration may increase blood lithium levels to toxic levels, and hepatic dysfunction from chronic alcohol use or hepatitis from intravenous substance use may adversely affect plasma levels of valproate and carbamazepine.⁶⁶ Dr. Skale noted that, ideally, clinicians would have access to patients' history, drug screening, and baseline laboratory results prior to prescribing medications.⁶⁷ However, many clinicians work in settings such as community mental health care facilities where severely ill patients are seen on a daily basis and the clinician is required to act quickly and effectively with limited information.

According to Dr. Skale, sleep disturbances can negatively impact patients' personal and workplace relationships, which can then trigger an urgent situation. To manage this biological factor, physicians should edu-


Table 4. Questions to Ask About a Patient When Managing an Urgent Situation

Is there a risk for suicidality/homicidality/aggression?
Is there a comorbid alcohol or other substance use disorder?
Is the patient currently experiencing psychotic symptoms?
Is this an acute manic episode?
Is this an acute depressive episode?
Is this a mixed state?
Is the patient pregnant?
Are there any medical concerns?
What medications/supplements is the patient taking?
Are there adherence issues?
What are the familial/social/occupational issues?

cate patients on the benefits of regulated sleep, which may reduce the occurrence of urgent situations and allow physicians to treat the primary psychiatric condition of bipolar disorder.

The APA guidelines,⁶⁷ Texas Medication Algorithm Project (TMAP),^{68,69} and Expert Consensus Guidelines⁷⁰ for the treatment of bipolar disorder offer rational, evidence-based intervention options for urgently ill patients. Dr. Skale stated that the recommended pharmacologic interventions should be tailored to individual patients and should also be effective, well-tolerated, and have a rapid onset of action. If the patient has had a known positive response to a medication in the past, that medication may be a good choice for the current episode. The patient may have confidence in this medication that has been effective and tolerated previously. For the treatment-naïve patient, the clinician should choose medication based on clinical presentation and other pertinent data such as comorbid medical issues, substance use disorders, and so on.

If the patient is in maintenance treatment, resolution of the acute situation may be achieved by the temporary increase of medication dose.^{67,69} Once the crisis is resolved, the patient's symptoms can typically be managed at a lower dose. When raising the dose of atypical antipsychotics, it is helpful to remind acutely manic patients that they will likely sleep regularly while taking

Figure 1. Biopsychosocial Model for Urgent Situations in Patients With Bipolar Disorder**Table 5. Medications Available With Alternate Delivery Mechanisms**

Medication	Potential Use
Intramuscular Formulations Ziprasidone ⁴¹ Olanzapine ³⁹ Aripiprazole ⁴⁰	In emergency department or inpatient setting where rapid control may be needed for safety reasons
Orally Disintegrating Tablets Risperidone ⁴⁸ Olanzapine ³⁹ Aripiprazole ⁴⁰	To help family/staff ensure adherence to oral dosing To help patients who do not like swallowing pills

the higher dose and that they will feel more calm and focused within the next few days. Conventional antipsychotic medications should be used with caution because of the risk of acute dystonic reactions. Dr. Skale noted that conventional antipsychotics are not highly recommended by the APA or TMAP treatment guidelines.^{67,69}

Dosages of mood stabilizers can also be raised during acute mania,^{67,71} but in Dr. Skale's clinical experience, for an outpatient in an urgent situation, adding lithium may not be the most effective intervention because lithium has a relatively long onset of action and a narrow therapeutic window. Further, raising the lithium level quickly to a high but safe range is easier in an inpatient setting than in an outpatient setting. If needed, the clinician may augment the current treatment with an-

other mood stabilizer or an atypical antipsychotic.

Short-term use of benzodiazepines may be considered if anxiety or insomnia is present.⁶⁷ Benzodiazepines can diminish manic symptoms quickly but are usually avoided with outpatients. If benzodiazepines are added in a hospital setting, they should be tapered and discontinued, if possible, prior to discharge.

Dr. Skale reiterated Dr. Garlow's recommendation that clinicians should minimize the use of antidepressants and, if antidepressants are used, clinicians must be cautious and watchful. Antidepressant treatment may need to be stopped if the patient is in a manic or mixed state.⁶⁷

Dr. Skale suggested using alternate delivery mechanisms if urgency is particularly critical or if patients have

trouble swallowing pills (Table 5). Finally, electroconvulsive therapy is an option in extremely urgent situations.⁶⁷

Psychological Management of Urgent Situations

Psychological factors that can contribute to patients' development of urgent situations are denial of having bipolar disorder, grief over personal loss (e.g., of job, of independence, of a loved one), stigma associated with the illness, and inability to cope with this chronic illness.

Dr. Skale outlined psychological tools that may be helpful in treating a patient who is urgently ill. Simply providing medical expertise and adopting a calm approach to the patient and family in distress is a part of good clinical care. When the acute crisis has ended, psychoeducation about the recurrent nature of this neurobiological illness, the need for ongoing pharmacotherapy, the recognition of unique triggers or target symptoms, and healthy coping mechanisms to keep stress under control can reduce the number of future recurrences and hospitalizations.⁷² Cognitive therapy specifically designed for relapse prevention in bipolar disorder is effective when used in conjunction with mood stabilizers.⁷³ Additionally, the combination of family and individual therapy, along with medication, can also offer protection from relapse.⁷⁴

Social Management of Urgent Situations

In addition to pharmacologic and psychological treatment interventions, the management of social factors that trigger mood episodes, such as financial difficulties, major life changes, and work and relationship problems, may require referral to a crisis stabilization center or help from support groups within the community. The National Alliance on Mental Illness is one such group, as is the Depression and Bipolar Support Alliance. The patient may also need substance abuse treatment services if alcohol or other substance abuse has caused or exacer-

bated the current acute episode.^{65,75} Dr. Skale stated that clinicians can also reassure the patient and family that there is hope that the patient will regain stability and act as a mediator to facilitate patient and family communication.

Addressing the Needs of the Suicidal Patient

Suicidality can be present in any phase of bipolar disorder.⁷⁶ APA guidelines⁶⁷ advocate that clinicians routinely assess for patients' suicidal or homicidal ideation, intent, and planning, as well as the availability of means to commit suicide and the lethality of those means.⁶⁷ Assessment for the presence of hallucinations and other psychiatric symptoms, including severe anxiety, and for the presence of alcohol or substance use is essential.⁶⁵ Clinicians should also assess patients' history of and seriousness of previous suicide attempts and self-harm and family history or recent exposure to suicide.⁷⁷ Dr. Skale stressed that using both pharmacologic and nonpharmacologic interventions is critical when suicidality is present.⁷⁶

Conclusion

Urgent situations present frequently in clinical settings. Optimizing outcomes for patients in crisis situations requires clinicians to rapidly and accurately assess the biological, psychological, and social precipitants of urgent situations and offer appropriate interventions. Dr. Skale concluded that this biopsychosocial approach offers the most useful opportunity for positive patient outcomes.

Summary

Dr. Jain reiterated that bipolar disorder is a common problem, and psychiatrists and nonpsychiatrists alike face urgent situations in clinical practice. Many stakeholders have a vested interest in optimizing patients' outcomes, including the patients themselves,⁷⁸ their families and care-

givers,^{78,79} their workplaces,⁸⁰ and society at large⁸¹; each one can be dramatically and adversely affected by the devastating impact of this debilitating disorder. Bipolar disorder not only can cause loss of life through suicide or other mortality but also can lead to family dysfunction and occupational and educational disruption,² and therefore, society as a whole suffers from urgently ill bipolar disorder patients who are not quickly and efficiently stabilized. In summation, Dr. Jain offered the following take-home points:

- Urgent presentations of bipolar disorder are common in all physicians' offices
- Accurate diagnosis of the various phases of bipolar disorder (manic, depressive, or mixed) is critical to effectively manage patients
- Quick and accurate assessment for patient self-harm or harm to others is necessary to treat urgent situations appropriately
- Offering systematic interventions that are rapidly effective is mandated, and focusing on efficacy and tolerability will help guide clinicians
- Full patient and support system involvement in psychoeducation and psychotherapy will help reduce the burden of bipolar disorder

Drug names: aripiprazole (Abilify), carbamazepine (Carbatrol, Equetro, and others), chlorpromazine (Thorazine, Sonazine, and others), divalproex sodium (Depakote), haloperidol (Haldol and others), lamotrigine (Lamictal and others), lithium (Eskalith, Lithobid, and others), lorazepam (Ativan and others), olanzapine (Zyprexa and Zyprexa Zydis), olanzapine-fluoxetine (Symbyax), quetiapine (Seroquel), risperidone (Risperdal), valproic acid (Depakene and others), ziprasidone (Geodon).

Disclosure of off-label usage: The chair has determined that, to the best of his knowledge, lamotrigine is not approved by the U.S. Food and Drug Administration for the acute treatment of bipolar depression, and intramuscular lorazepam and intramuscular ziprasidone are not approved for agitation in bipolar disorder.

REFERENCES

1. Merriam-Webster's Collegiate Dictionary, Tenth Edition. Springfield, Mass: Merriam-Webster, Inc; 2002
2. Dutta R, Boydell J, Kennedy N, et al. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. *Psychol Med* 2007;1-9. E-pub ahead of print
3. Feldmann TB. Bipolar disorder and violence. *Psychiatr Q* 2001;72:119-129
4. Corrigan PW, Watson AC. Findings from the National Comorbidity Survey on the frequency of violent behavior in individuals with psychiatric disorders. *Psychiatry Res* 2005;136:153-162
5. Swanson JW, Holzer CEI, Ganju VK, et al. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. *Hosp Community Psychiatry* 1990;41:761-770
6. Quanbeck CD, McDermott BE, Frye MA. Clinical and legal characteristics of inmates with bipolar disorder. *Curr Psychiatry Rep* 2005;7:478-484
7. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. *Bipolar Disord* 2007;9:183-196
8. Lam D, Donaldson C, Brown Y, et al. Burden and marital and sexual satisfaction in the partners of bipolar patients. *Bipolar Disord* 2005;7:431-440
9. Kessler RC, Akiskal HL, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. *Am J Psychiatry* 2006;163:1561-1568
10. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the systematic treatment enhancement program. *Arch Gen Psychiatry* 2007;64:419-426
11. Miklowitz DJ. An update on the role of psychotherapy in the management of bipolar disorder. *Curr Psychiatry Rep* 2006;8:498-503
12. Rizvi S, Zaretsky AE. Psychotherapy through the phases of bipolar disorder: Evidence for general efficacy and differential effects. *J Clin Psychol* 2007;63:491-506
13. Akiskal HS. The dark side of bipolarity: detecting bipolar depression in its pleomorphic expressions. *J Affect Disord* 2005;84:107-115
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
15. McElroy SL, Strakowski SM, Keck PE Jr, et al. Differences and similarities in mixed and pure mania. *Compr Psychiatry* 1995;36:187-194
16. Benazzi F. Mixed states in bipolar II disorder: should full hypomania always be required? *Psychiatry Res* 2004;127:247-257
17. Perugi G, Akiskal HS. Emerging concepts of mixed states: a longitudinal perspective. In: Marneros A, Goodwin F, eds. *Bipolar Disorders: Mixed States, Rapid Cycling, and Atypical Forms*. Cambridge, England: Cambridge University Press; 2005:45-60
18. Akiskal HS, Mallya G. Criteria for the "soft" bipolar spectrum: treatment

- implications. *Psychopharmacol Bull* 1987;23:68–73
19. Swann AC, Bowden CL, Morris D, et al. Depression during mania. *Arch Gen Psychiatry* 1997;54:37–42
 20. Dilsaver SC, Chen YR, Shoaib AM, et al. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. *Am J Psychiatry* 1999;156:426–430
 21. Suppes T, Mintz J, McElroy SL, et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. *Arch Gen Psychiatry* 2005;62:1089–1096
 22. Post RM, Rubinow DR, Uhde TW, et al. Dysphoric mania: clinical and biological correlates. *Arch Gen Psychiatry* 1989;46:353–358
 23. Hawton K, Sutton L, Haw C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. *J Clin Psychiatry* 2005;66:693–704
 24. Rihmer Z, Kiss K. Bipolar disorders and suicidal behaviour. *Bipolar Disord* 2002;4(suppl 1):21–25
 25. Dilsaver SC, Chen YW, Swann AC, et al. Suicidality in patients with pure and depressive mania. *Am J Psychiatry* 1994;151:1312–1315
 26. Strakowski SM, McElroy SL, Keck PE Jr, et al. Suicidality among patients with mixed and manic bipolar disorder. *Am J Psychiatry* 1996;153:674–676
 27. Marneros A, Rottig S, Wenzel A, et al. Affective and schizoaffective mixed states. *Eur Arch Psychiatry Clin Neurosci* 2004;254:76–81
 28. Hirschfeld RM, Cass AR, Holt DC, et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. *J Am Board Fam Pract* 2005;18:233–239
 29. Manning JS, Haykal RF, Connor PD, et al. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. *Compr Psychiatry* 1997;38:102–108
 30. Swann AC, Geller B, Post RM, et al. Practical clues to early recognition of bipolar disorder: a primary care approach. *Primary Care Companion J Clin Psychiatry* 2005;7:15–21
 31. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. *J Clin Psychiatry* 2003;64:161–174
 32. Calabrese JR, Hirschfeld RMA, Reed M, et al. Impact of bipolar disorder on a US community sample. *J Clin Psychiatry* 2003;64:425–432
 33. McIntyre RS, Soczynska JK, Bottas A, et al. Anxiety disorders and bipolar disorder: a review. *Bipolar Disord* 2006;8:665–676
 34. Vornick LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. *J Clin Psychiatry* 2006;67(suppl 7):24–30
 35. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. *Bipolar Disord* 2003;5:421–433
 36. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescriptions for U.S. patients with diagnoses of bipolar disorders. *Psychiatr Serv* 2007;58:85–91
 37. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. *Am J Psychiatry* 2003;160:1286–1290
 38. Valtonen H, Suominen K, Mantere O, et al. Suicidal ideation and attempts in bipolar I and II disorders. *J Clin Psychiatry* 2005;66:1456–1462
 39. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2006. Available at: <http://pi.lilly.com/us/zyprexa-pi.pdf>. Accessed April 17, 2007
 40. Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceutical; 2006. Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=101&key=PPI. Accessed April 25, 2007
 41. Geodon (ziprasidone). Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007
 42. Battaglia J. Pharmacological management of acute agitation. *Drugs* 2005;65:1207–1222
 43. Eskalith (lithium carbonate). Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006
 44. Depakote ER divalproex sodium extended-release tablets [package insert]. North Chicago, Ill: Abbott Laboratories; 2006. Available at: <http://www.rxabbott.com/pdf/dep3.pdf>. Accessed May 17, 2007
 45. Equetro TM (carbamazepine) extended-release capsules [package insert]. Wayne, Pa: Shire US Inc; 2005. Available at <http://www.fda.gov/cder/foi/label/2006/021710s0031bl.pdf>. Accessed May 17, 2007
 46. Gajwani P, Kemp DE, Muzina DJ, et al. Acute treatment of mania: an update on new medications. *Curr Psychiatry Rep* 2006;8:504–509
 47. Thorazine (chlorpromazine). Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR; 2003
 48. Risperdal [package insert]. Titusville, NJ: Janssen; 2006. Available at: <http://www.risperdal.com/risperdal/shared/risperdal.pdf>. Accessed April 17, 2007
 49. Seroquel [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals; 2006. Available at: <http://www.astrazeneca-us.com/pi/seroquel.pdf>. Accessed January 31, 2007
 50. Symbyax (olanzapine-fluoxetine). Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007
 51. Malhi GS, Mitchell PB, Salim S. Bipolar depression: management options. *CNS Drugs* 2003;17:9–25
 52. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. *Am J Psychiatry* 2006;163:232–239
 53. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. *Am J Psychiatry* 2006;163:313–315
 54. Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. *Bipolar Disord* 2003;5:396–406
 55. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. *Am J Psychiatry* 2004;161:1537–1547
 56. Daban C, Colom F, Sanchez-Moreno J, et al. Clinical correlates of first-episode polarity in bipolar disorder. *Compr Psychiatry* 2006;47:433–437
 57. Keck PE Jr., Perlis RH, Otto MW, et al. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. *Postgrad Med Special Report* 2004:1–120
 58. Keck PE Jr. Evaluation and management of breakthrough depressive episodes. *J Clin Psychiatry* 2004;65(suppl 10):11–15
 59. Lamictal [package insert]. Greenville, NC: GlaxoSmithKline; 2005. Available at: http://www.fda.gov/cder/foi/label/2006/020241s10s21s25s26s27_020764s3s14s18s19s20bl.pdf. Accessed May 17, 2007
 60. Miles CP. Conditions predisposing to suicide: a review. *J Nerv Ment Dis* 1977;164:231–246
 61. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. *Neurology* 2005;64:961–965
 62. Tatum WO. In utero antiepileptic drug exposure. *Expert Rev Neurother* 2006;6:1785–1787
 63. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. *J Clin Psychiatry* 1998;59(suppl 2):29–33
 64. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. *JAMA* 1990;264:2511–2518
 65. Tondo L, Baldessarini RJ, Hennen J, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. *J Clin Psychiatry* 1999;60(suppl 2):63–69
 66. Sonne SC, Brady KT. Substance abuse and bipolar comorbidity. *Psychiatr Clin North Am* 1999;22:609–627
 67. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder [revision]. *Am J Psychiatry* 2002;159:1–50
 68. Dennehy EB, Suppes T, Rush AJ, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? results from the Texas Medication Algorithm Project. *Psychol Med* 2005;35:1695–1706
 69. Suppes T, Swann AC, Dennehy EB, et al. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. *J Clin Psychiatry* 2001;62:439–447
 70. Frances A, Docherty JP, Kahn DA. The Expert Consensus Guidelines Series: treatment of bipolar disorder. *J Clin Psychiatry* 1996;57(suppl 12A):1–88
 71. Hirschfeld RM, Allen MH, McEvoy JP, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. *J Clin Psychiatry*

ACADEMIC HIGHLIGHTS

- 1999;60:815–818
72. Colom F, Vieta E, Martinez-Arán A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar disorder whose disease is in remission. *Arch Gen Psychiatry* 2003;60:402–407
73. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar disorder: outcome of the first year. *Arch Gen Psychiatry* 2003;60:145–152
74. Miklowitz DJ, Richards JA, George EL, et al. Integrated family and individual therapy for bipolar disorder: results of a treatment development study. *J Clin Psychiatry* 2003;64:182–191
75. Potash JB, Kane HS, Chiu YF, et al. Attempted suicide and alcoholism in bipolar disorder: clinical and familial relationships. *Am J Psychiatry* 2000;157:2048–2050
76. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorder. *J Clin Psychiatry* 1999;60(suppl 2):53–56
77. Goodwin FK, Jamison KR. *Manic-Depressive Illness*. New York, NY: Oxford University Press; 1990
78. Elgie R, Morselli PL. Social functioning in bipolar patients: the perception and perspective of patients, relatives and advocacy organizations: a review. *Bipolar Disord* 2007;9:144–157
79. Ogilvie AD, Morant N, Goodwin GM. The burden of informal caregivers of people with bipolar disorder. *Bipolar Disord* 2005;7(suppl 1):25–32
80. Waghorn G, Chant D, Jaeger J. Employment functioning and disability among community residents with bipolar affective disorder: results from an Australian community survey. *Bipolar Disord* 2007;9:166–182
81. Hirschfeld RM, Vornik RA. Bipolar disorder: costs and comorbidity. *Am J Manag Care* 2005;11(suppl 3):S85–S90

For the CME Posttest for this ACADEMIC HIGHLIGHTS, see pages 1153–1155.
